{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:45:04Z","timestamp":1760298304169},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,12,3]],"date-time":"2010-12-03T00:00:00Z","timestamp":1291334400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s11934-010-0156-y","type":"journal-article","created":{"date-parts":[[2010,12,2]],"date-time":"2010-12-02T11:25:56Z","timestamp":1291289156000},"page":"47-55","source":"Crossref","is-referenced-by-count":20,"title":["Impact of Genetics on the Diagnosis and Treatment of Renal Cancer"],"prefix":"10.1007","volume":"12","author":[{"given":"Eric A.","family":"Singer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gennady","family":"Bratslavsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Middelton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramaprasad","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Marston","family":"Linehan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,12,3]]},"reference":[{"key":"156_CR1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","volume":"60","author":"A Jemal","year":"2010","unstructured":"Jemal A, Siegel R, Xu J, Ward E: Cancer Statistics, 2010. CA Cancer J Clin 2010, 60:277\u2013300.","journal-title":"CA Cancer J Clin"},{"key":"156_CR2","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1001\/jama.281.17.1628","volume":"281","author":"WH Chow","year":"1999","unstructured":"Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr: Rising incidence of renal cell cancer in the United States. JAMA 1999, 281:1628\u20131631.","journal-title":"JAMA"},{"key":"156_CR3","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/jnci\/djj362","volume":"98","author":"JM Hollingsworth","year":"2006","unstructured":"Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK: Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 2006, 98:1331\u20131334.","journal-title":"J Natl Cancer Inst"},{"key":"156_CR4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G","volume":"183","author":"G Kovacs","year":"1997","unstructured":"Kovacs G, Akhtar M, Beckwith BJ, et al.: The Heidelberg classification of renal cell tumours. J Pathol 1997, 183:131\u2013133.","journal-title":"J Pathol"},{"key":"156_CR5","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1097\/01.ju.0000096060.92397.ed","volume":"170","author":"WM Linehan","year":"2003","unstructured":"Linehan WM, Walther MM, Zbar B: The genetic basis of cancer of the kidney. J Urol 2003, 170:2163\u20132172.","journal-title":"J Urol"},{"key":"156_CR6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrurol.2010.47","volume":"7","author":"WM Linehan","year":"2010","unstructured":"Linehan WM, Srinivasan R, Schmidt LS: The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 2010, 7:277\u2013285.","journal-title":"Nat Rev Urol"},{"key":"156_CR7","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.eururo.2009.09.002","volume":"56","author":"G Lorenzo Di","year":"2009","unstructured":"Di Lorenzo G, Autorino R, Sternberg CN: Metastatic renal cell carcinoma: recent advances in the targeted therapy era. Eur Urol 2009, 56:959\u2013971.","journal-title":"Eur Urol"},{"key":"156_CR8","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1200\/JCO.2008.19.9836","volume":"27","author":"BI Rini","year":"2009","unstructured":"\u2022 Rini BI: Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol 2009, 27:3225\u20133234. This is an excellent review of systemic therapy for metastatic RCC.","journal-title":"J Clin Oncol"},{"key":"156_CR9","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2009.27.0660","volume":"28","author":"ME Robson","year":"2010","unstructured":"\u2022\u2022 Robson ME, Storm CD, Weitzel J, et al.: American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2010, 28:893\u2013901. This is the American Society of Clinical Oncology\u2019s updated policy statement on the use of genetic testing in oncology.","journal-title":"J Clin Oncol"},{"key":"156_CR10","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMra043172","volume":"353","author":"HT Cohen","year":"2005","unstructured":"Cohen HT, McGovern FJ: Renal-cell carcinoma. N Engl J Med 2005, 353:2477\u20132490.","journal-title":"N Engl J Med"},{"key":"156_CR11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.urolonc.2008.11.001","volume":"27","author":"I Rosner","year":"2009","unstructured":"Rosner I, Bratslavsky G, Pinto PA, Linehan WM: The clinical implications of the genetics of renal cell carcinoma. Urol Oncol 2009, 27:131\u2013136.","journal-title":"Urol Oncol"},{"key":"156_CR12","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0022-5347(01)66674-6","volume":"154","author":"MM Walther","year":"1995","unstructured":"Walther MM, Lubensky IA, Venzon D, et al.: Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. J Urol 1995, 154:2010\u20132014.","journal-title":"J Urol"},{"key":"156_CR13","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.8493574","volume":"260","author":"F Latif","year":"1993","unstructured":"Latif F, Tory K, Gnarra J, et al.: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260:1317\u20131320.","journal-title":"Science"},{"key":"156_CR14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K","volume":"12","author":"C Stolle","year":"1998","unstructured":"Stolle C, Glenn G, Zbar B, et al.: Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 1998, 12:417\u2013423.","journal-title":"Hum Mutat"},{"key":"156_CR15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/ng0594-85","volume":"7","author":"JR Gnarra","year":"1994","unstructured":"Gnarra JR, Tory K, Weng Y, et al.: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994, 7:85\u201390.","journal-title":"Nat Genet"},{"key":"156_CR16","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/humu.1380050109","volume":"5","author":"F Chen","year":"1995","unstructured":"Chen F, Kishida T, Yao M, et al.: Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 1995, 5:66\u201375.","journal-title":"Hum Mutat"},{"key":"156_CR17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/humu.10302","volume":"23","author":"JK Maranchie","year":"2004","unstructured":"Maranchie JK, Afonso A, Albert PS, et al.: Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Hum Mutat 2004, 23:40\u201346.","journal-title":"Hum Mutat"},{"key":"156_CR18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/humu.20385","volume":"28","author":"KR Ong","year":"2007","unstructured":"Ong KR, Woodward ER, Killick P, et al.: Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat 2007, 28:143\u2013149.","journal-title":"Hum Mutat"},{"key":"156_CR19","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1126\/science.7660122","volume":"269","author":"DR Duan","year":"1995","unstructured":"Duan DR, Pause A, Burgess WH, et al.: Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 1995, 269:1402\u20131406.","journal-title":"Science"},{"key":"156_CR20","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.7660130","volume":"269","author":"A Kibel","year":"1995","unstructured":"Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG Jr: Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 1995, 269:1444\u20131446.","journal-title":"Science"},{"key":"156_CR21","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1073\/pnas.94.6.2156","volume":"94","author":"A Pause","year":"1997","unstructured":"Pause A, Lee S, Worrell RA, et al.: The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A 1997, 94:2156\u20132161.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"156_CR22","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1059796","volume":"292","author":"P Jaakkola","year":"2001","unstructured":"Jaakkola P, Mole DR, Tian YM, et al.: Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292:468\u2013472.","journal-title":"Science"},{"key":"156_CR23","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1126\/science.284.5414.657","volume":"284","author":"T Kamura","year":"1999","unstructured":"Kamura T, Koepp DM, Conrad MN, et al.: Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 1999, 284:657\u2013661.","journal-title":"Science"},{"key":"156_CR24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","volume":"399","author":"PH Maxwell","year":"1999","unstructured":"Maxwell PH, Wiesener MS, Chang GW, et al.: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271\u2013275.","journal-title":"Nature"},{"key":"156_CR25","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1172\/JCI8161","volume":"104","author":"M Ohh","year":"1999","unstructured":"Ohh M, Takagi Y, Aso T, et al.: Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. J Clin Invest 1999, 104:1583\u20131591.","journal-title":"J Clin Invest"},{"key":"156_CR26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/35017054","volume":"2","author":"M Ohh","year":"2000","unstructured":"Ohh M, Park CW, Ivan M, et al.: Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000, 2:423\u2013427.","journal-title":"Nat Cell Biol"},{"key":"156_CR27","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1126\/science.284.5413.455","volume":"284","author":"CE Stebbins","year":"1999","unstructured":"Stebbins CE, Kaelin WG Jr, Pavletich NP: Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 1999, 284:455\u2013461.","journal-title":"Science"},{"key":"156_CR28","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ctrv.2006.12.005","volume":"33","author":"EC Nelson","year":"2007","unstructured":"Nelson EC, Evans CP, Lara PN Jr: Renal cell carcinoma: current status and emerging therapies. Cancer Treat Rev 2007, 33:299\u2013313.","journal-title":"Cancer Treat Rev"},{"key":"156_CR29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0094-0143(21)00489-4","volume":"20","author":"A Yagoda","year":"1993","unstructured":"Yagoda A, Petrylak D, Thompson S: Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993, 20:303\u2013321.","journal-title":"Urol Clin North Am"},{"key":"156_CR30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11523-010-0148-3","volume":"5","author":"EA Singer","year":"2010","unstructured":"Singer EA, Bratslavsky G, Linehan WM, Srinivasan R: Targeted therapies for non-clear renal cell carcinoma. Target Oncol 2010, 5:119\u2013129.","journal-title":"Target Oncol"},{"key":"156_CR31","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1470-2045(09)70380-8","volume":"11","author":"KA Furge","year":"2010","unstructured":"\u2022 Furge KA, MacKeigan JP, Teh BT: Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new. Lancet Oncol 2010, 11:571\u2013578. The authors review the use of molecularly targeted kinase inhibitors and identify promising new agents that may have activity against RCC.","journal-title":"Lancet Oncol"},{"key":"156_CR32","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0022-5347(17)35015-2","volume":"151","author":"B Zbar","year":"1994","unstructured":"Zbar B, Tory K, Merino M, et al.: Hereditary papillary renal cell carcinoma. J Urol 1994, 151:561\u2013566.","journal-title":"J Urol"},{"key":"156_CR33","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ng0597-68","volume":"16","author":"L Schmidt","year":"1997","unstructured":"Schmidt L, Duh FM, Chen F, et al.: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997, 16:68\u201373.","journal-title":"Nat Genet"},{"key":"156_CR34","first-page":"1719","volume":"58","author":"L Schmidt","year":"1998","unstructured":"Schmidt L, Junker K, Weirich G, et al.: Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res 1998, 58:1719\u20131722.","journal-title":"Cancer Res"},{"key":"156_CR35","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1038\/sj.onc.1202547","volume":"18","author":"L Schmidt","year":"1999","unstructured":"Schmidt L, Junker K, Nakaigawa N, et al.: Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999, 18:2343\u20132350.","journal-title":"Oncogene"},{"key":"156_CR36","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3346\/jkms.2006.21.4.672","volume":"21","author":"JS Choi","year":"2006","unstructured":"Choi JS, Kim MK, Seo JW, et al.: MET expression in sporadic renal cell carcinomas. J Korean Med Sci 2006, 21:672\u2013677.","journal-title":"J Korean Med Sci"},{"key":"156_CR37","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2174\/1566524043359674","volume":"4","author":"PG Dharmawardana","year":"2004","unstructured":"Dharmawardana PG, Giubellino A, Bottaro DP: Hereditary papillary renal carcinoma type I. Curr Mol Med 2004, 4:855\u2013868.","journal-title":"Curr Mol Med"},{"key":"156_CR38","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/sj.onc.1201983","volume":"17","author":"J Fischer","year":"1998","unstructured":"Fischer J, Palmedo G, von Knobloch R, et al.: Duplication and overexpression of the mutant allele of the MET proto- oncogene in multiple hereditary papillary renal cell tumours. Oncogene 1998, 17:733\u2013740.","journal-title":"Oncogene"},{"key":"156_CR39","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0022-5347(01)67601-8","volume":"153","author":"B Zbar","year":"1995","unstructured":"Zbar B, Glenn GM, Lubensky IA, et al.: Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol 1995, 153:907\u2013912.","journal-title":"J Urol"},{"key":"156_CR40","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1073\/pnas.051633798","volume":"98","author":"V Launonen","year":"2001","unstructured":"Launonen V, Vierimaa O, Kiuru M, et al.: Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A 2001, 98:3387\u20133392.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"156_CR41","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ng849","volume":"30","author":"IP Tomlinson","year":"2002","unstructured":"Tomlinson IP, Alam NA, Rowan AJ, et al.: Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002, 30:406\u2013410.","journal-title":"Nat Genet"},{"key":"156_CR42","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.juro.2007.01.155","volume":"177","author":"RL Grubb 3rd","year":"2007","unstructured":"Grubb RL 3rd, Franks ME, Toro J, et al.: Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol 2007, 177:2074\u20132080.","journal-title":"J Urol"},{"key":"156_CR43","doi-asserted-by":"crossref","first-page":"671s","DOI":"10.1158\/1078-0432.CCR-06-1870","volume":"13","author":"WM Linehan","year":"2007","unstructured":"Linehan WM, Pinto PA, Srinivasan R, et al.: Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res 2007, 13:671s\u2013679s.","journal-title":"Clin Cancer Res"},{"key":"156_CR44","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ccr.2005.06.017","volume":"8","author":"JS Isaacs","year":"2005","unstructured":"Isaacs JS, Jung YJ, Mole DR, et al.: HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005, 8:143\u2013153.","journal-title":"Cancer Cell"},{"key":"156_CR45","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.med.042808.171650","volume":"61","author":"WM Linehan","year":"2010","unstructured":"Linehan WM, Bratslavsky G, Pinto PA, et al.: Molecular diagnosis and therapy of kidney cancer. Annu Rev Med 2010, 61:329\u2013343.","journal-title":"Annu Rev Med"},{"key":"156_CR46","doi-asserted-by":"crossref","unstructured":"Srinivasan R, Linehan WM, Vaishampayan U, et al.: A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET\/VEGFR2 inhibitor, in patients (pts) with papillary renal carcinoma (PRC). J Clin Oncol 2009, 27(May 20 Supplement):5103.","DOI":"10.1200\/jco.2008.26.15_suppl.5103"},{"key":"156_CR47","doi-asserted-by":"crossref","first-page":"5788","DOI":"10.1200\/JCO.2008.18.8821","volume":"27","author":"MS Gordon","year":"2009","unstructured":"Gordon MS, Hussey M, Nagle RB, et al.: Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol 2009, 27:5788\u20135793.","journal-title":"J Clin Oncol"},{"key":"156_CR48","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2007.13.3223","volume":"26","author":"TK Choueiri","year":"2008","unstructured":"Choueiri TK, Plantade A, Elson P, et al.: Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008, 26:127\u2013131.","journal-title":"J Clin Oncol"},{"key":"156_CR49","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2002.11.123","volume":"20","author":"RJ Motzer","year":"2002","unstructured":"Motzer RJ, Bacik J, Mariani T, et al.: Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002, 20:2376\u20132381.","journal-title":"J Clin Oncol"},{"key":"156_CR50","unstructured":"National Institutes of Health: A phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell carcinoma (HLRCC) or sporadic papillary renal cancer. Available at http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01130519 . Accessed October 2010."},{"key":"156_CR51","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/00000478-200305000-00005","volume":"27","author":"JC Cheville","year":"2003","unstructured":"Cheville JC, Lohse CM, Zincke H, et al.: Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003, 27:612\u2013624.","journal-title":"Am J Surg Pathol"},{"key":"156_CR52","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1200\/JCO.2005.07.055","volume":"23","author":"JJ Patard","year":"2005","unstructured":"Patard JJ, Leray E, Rioux-Leclercq N, et al.: Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005, 23:2763\u20132771.","journal-title":"J Clin Oncol"},{"key":"156_CR53","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1097\/00000478-200212000-00002","volume":"26","author":"CP Pavlovich","year":"2002","unstructured":"Pavlovich CP, Walther MM, Eyler RA, et al.: Renal tumors in the Birt-Hogg-Dub\u00e9 syndrome. Am J Surg Pathol 2002, 26:1542\u20131552.","journal-title":"Am J Surg Pathol"},{"key":"156_CR54","first-page":"393","volume":"11","author":"B Zbar","year":"2002","unstructured":"Zbar B, Alvord WG, Glenn G, et al.: Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dub\u00e9 syndrome. Cancer Epidemiol Biomarkers Prev 2002, 11:393\u2013400.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"156_CR55","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1535-6108(02)00104-6","volume":"2","author":"ML Nickerson","year":"2002","unstructured":"Nickerson ML, Warren MB, Toro JR, et al.: Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dub\u00e9 syndrome. Cancer Cell 2002, 2:157\u2013164.","journal-title":"Cancer Cell"},{"key":"156_CR56","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1086\/323744","volume":"69","author":"LS Schmidt","year":"2001","unstructured":"Schmidt LS, Warren MB, Nickerson ML, et al.: Birt-Hogg-Dub\u00e9 syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet 2001, 69:876\u2013882.","journal-title":"Am J Hum Genet"},{"key":"156_CR57","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1086\/430842","volume":"76","author":"LS Schmidt","year":"2005","unstructured":"Schmidt LS, Nickerson ML, Warren MB, et al.: Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dub\u00e9 syndrome. Am J Hum Genet 2005, 76:1023\u20131033.","journal-title":"Am J Hum Genet"},{"key":"156_CR58","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/jnci\/dji154","volume":"97","author":"CD Vocke","year":"2005","unstructured":"Vocke CD, Yang Y, Pavlovich CP, et al.: High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dub\u00e9 -associated renal tumors. J Natl Cancer Inst 2005, 97:931\u2013935. (Published erratum appears in J Natl Cancer Inst 2005, 97:1096.)","journal-title":"J Natl Cancer Inst"},{"key":"156_CR59","doi-asserted-by":"crossref","first-page":"15552","DOI":"10.1073\/pnas.0603781103","volume":"103","author":"M Baba","year":"2006","unstructured":"Baba M, Hong SB, Sharma N, et al.: Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A 2006, 103:15552\u201315557.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"156_CR60","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.gene.2008.02.022","volume":"415","author":"H Hasumi","year":"2008","unstructured":"Hasumi H, Baba M, Hong SB, et al.: Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene 2008, 415:60\u201367.","journal-title":"Gene"},{"key":"156_CR61","doi-asserted-by":"crossref","first-page":"18722","DOI":"10.1073\/pnas.0908853106","volume":"106","author":"Y Hasumi","year":"2009","unstructured":"Hasumi Y, Baba M, Ajima R, et al.: Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci U S A 2009, 106:18722\u201318727.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"156_CR62","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/jnci\/djm288","volume":"100","author":"M Baba","year":"2008","unstructured":"Baba M, Furihata M, Hong SB, et al.: Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1\/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst 2008, 100:140\u2013154.","journal-title":"J Natl Cancer Inst"},{"key":"156_CR63","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0022-5347(05)68930-6","volume":"161","author":"MM Walther","year":"1999","unstructured":"Walther MM, Choyke PL, Glenn G, et al.: Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol 1999, 161:1475\u20131479.","journal-title":"J Urol"},{"key":"156_CR64","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0022-5347(05)66524-X","volume":"165","author":"JC Herring","year":"2001","unstructured":"Herring JC, Enquist EG, Chernoff A, et al.: Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J Urol 2001, 165:777\u2013781.","journal-title":"J Urol"},{"key":"156_CR65","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.juro.2009.06.036","volume":"182","author":"R Boris","year":"2009","unstructured":"Boris R, Proano M, Linehan WM, et al.: Initial experience with robot assisted partial nephrectomy for multiple renal masses. J Urol 2009, 182:1280\u20131286.","journal-title":"J Urol"},{"key":"156_CR66","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11934-009-0085-9","volume":"11","author":"EA Singer","year":"2010","unstructured":"Singer EA, Bratslavsky G: Management of locally recurrent kidney cancer. Curr Urol Rep 2010, 11:15\u201321.","journal-title":"Curr Urol Rep"},{"key":"156_CR67","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0022-5347(01)67602-X","volume":"153","author":"MM Walther","year":"1995","unstructured":"Walther MM, Choyke PL, Weiss G, et al.: Parenchymal sparing surgery in patients with hereditary renal cell carcinoma. J Urol 1995, 153:913\u2013916.","journal-title":"J Urol"},{"key":"156_CR68","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.juro.2008.09.017","volume":"181","author":"WC Huang","year":"2009","unstructured":"\u2022 Huang WC, Elkin EB, Levey AS, et al.: Partial nephrectomy versus radical nephrectomy in patients with small renal tumors\u2014is there a difference in mortality and cardiovascular outcomes? J Urol 2009, 181:55\u201361. This article illustrates the importance of nephron-sparing surgery for renal tumors.","journal-title":"J Urol"},{"key":"156_CR69","doi-asserted-by":"crossref","unstructured":"Linehan WM, Zbar B: Focus on kidney cancer. Cancer Cell 2004, 6:223\u2013228. (Published erratum appears in Cancer Cell 2004, 223\u2013228.)","DOI":"10.1016\/j.ccr.2004.09.006"},{"key":"156_CR70","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1517\/14712598.8.6.779","volume":"8","author":"EC Pfaffenroth","year":"2008","unstructured":"Pfaffenroth EC, Linehan WM: Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin Biol Ther 2008, 8:779\u2013790.","journal-title":"Expert Opin Biol Ther"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-010-0156-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11934-010-0156-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-010-0156-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,14]],"date-time":"2021-11-14T14:37:44Z","timestamp":1636900664000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11934-010-0156-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,3]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["156"],"URL":"https:\/\/doi.org\/10.1007\/s11934-010-0156-y","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,3]]}}}